We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Tufts Medical Center, Boston, MA, USA
Prof. Harrison Farber is a professor of medicine and director of the Pulmonary Embolism Emergency Response Team (PERT) and the Pulmonary Hypertension Fellowship at Tufts Medical Center, Boston, USA. read more
Prof. Farber’s research focuses on the response of the pulmonary vasculature to injury and endothelial cell biology. His laboratory investigates the response of the pulmonary vasculature in different aetiologies of pulmonary hypertension (PH), in particular, scleroderma, using genomic and proteomic approaches to identify unique molecules as potential therapeutic targets for PH and associated diseases. Prof. Farber serves on the steering committees for several registries for PH and PAH and is very active in developing risk assessment tools for both conditions.
Prof. Harrison Farber discloses: Advisory board or panel fees from Acceleron Pharma, Actelion, Aerami Therapeutics, Aerovate Therapeutics, Altavant Sciences and United Therapeutics. Speaker’s bureau fees from Bayer.
University Hospitals Leuven, Belgium
Prof. Marion Delcroix is a professor of medicine and respiratory physiology at the Universities of Leuven and Kortrijk, Belgium. She is head of the pulmonary hypertension (PH) programme, in charge of the respiratory high care unit, and vice chair of the Council for Rare Diseases at the University Hospitals Leuven. read more
Prof. Delcroix’s research interests focus on pulmonary circulation and gas exchange, cardiac imaging, and the role of inflammation in the pathogenesis of PAH and chronic thromboembolic pulmonary hypertension (CTEPH). Prof. Delcroix is a founding member and chair of the International CTEPH Association. She was a core PH member of the European Reference Network-LUNG, former assembly head of the European Respiratory Society (ERS), Pulmonary Vascular Diseases Assembly, and co-chair of the severe Pulmonary Hypertension mAnagement acROSs Europe (PHAROS) ERS Clinical Research Collaboration. Prof. Delcroix was also a scientific board member of the World Symposia on Pulmonary Hypertension Association. She is a fellow of the European Society of Cardiology (ESC) and the ERS, and co-chair of the ESC/ERS 2022 PH guidelines. Prof. Delcroix was a former associate editor of the European Respiratory Journal and is currently a deputy editor of The Journal of Heart and Lung Transplantation.
Prof. Marion Delcroix discloses: Speaker or consultancy fees from Acceleron Pharma, Altavant Sciences, AOP Health, Bayer, Ferrer, Gossamer Bio, Inari Medical, Janssen, MSD and United Therapeutics. Grants/research support from Janssen.
University of Cologne, Germany
Prof. Stephan Rosenkranz is an interventional cardiologist and head of the Pulmonary Hypertension Center at the University of Cologne, Germany, and also leads the Cologne Cardiovascular Research Center (CCRC). read more
Prof. Rosenkranz is a past chair of the European Society of Cardiology (ESC) Working Group on Pulmonary Circulation and Right Ventricular Function, and served as co-chair of the 2022 ESC/European Respiratory Society guidelines for pulmonary hypertension (PH). His research interests include cardiopulmonary interaction and right ventricular function in left-sided heart disease, as well as signal transduction and the biological importance of receptor tyrosine kinases and stress signalling in cardiovascular disease. He has been involved in many clinical trials in the fields of atherosclerosis, heart failure and PH, and has received numerous scientific awards.
Prof. Stephan Rosenkranz discloses: Speaker or consultancy fees from Abbott, Acceleron Pharma, Actelion, Aerovate Therapeutics, Altavant Sciences, AOP Health, AstraZeneca, Bayer, Boehringer Ingelheim, Edwards Lifesciences, Ferrer, Gossamer Bio, Janssen, MSD, United Therapeutics and Vifor Pharma. Grants/research support from AstraZeneca, Bayer and Janssen.